Valproic acid increases CD133 positive cells that show low sensitivity to cytostatics in neuroblastoma

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Khalil, Mohamed Ashraf ^a   Hraběta, Jan ^a   Groh, Tomáš ^b   Procházka, Pavel ^b,c   Doktorová, Helena ^a   Eckschlager, Tomáš ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; CASPASE 3; CD133 ANTIGEN; DECITABINE; HISTONE H3; HISTONE H4; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHOPROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; VALPROIC ACID; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; TUMOR MARKER;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOSTASIS; DRUG RESISTANCE; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CELL CYCLE; DRUG EFFECTS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NEUROBLASTOMA; TUMOR CELL LINE; WESTERN BLOTTING;

AC133 ANTIGEN; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CYTOSTATIC AGENTS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; NEUROBLASTOMA; VALPROIC ACID;

EID: 84990898336     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162916     Document Type: Article

References (66)

1. Chateauvieux S, Morceau F, Dicato M., Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010; 2010:1-18. doi:10.1155/2010/479364
2. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997; 389:349-352. doi: 10.1038/38664 PMID: 9311776
3. Boudadi E, Stower H, Halsall J.A., Rutledge CE, Leeb M, Wutz A, et al The histone deacetylase inhibitor sodium valproate causes limited transcriptional change in mouse embryonic stem cells but selectively overrides Polycomb-mediated Hoxb silencing. Epigenetics Chromatin. 2013; 6:11. doi: 10.1186/1756-8935-6-11 PMID: 23634885
4. Hrebackova J, Hrabeta J, Eckschlager T. Valproic acid in the complex therapy of malignant tumors. Curr Drug Targets. 2010; 11: 361-379. doi: 10.2174/138945010790711923 PMID: 20214599
5. Lee H-Z, Kwitkowski V.E., Del Valle PL, Ricci MS, Saber H, Habtemariam BA, et al FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. Clin Cancer Res. 2015; 21:2666-2670. doi: 10.1158/1078-0432.CCR-14-3119 PMID: 25802282
6. Chen CL, Sung J, Cohen M., Chowdhury WH, Sachs MD, Li Y, et al Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther. 2006; 319:533-542. doi: 10.1124/jpet.106.106658 PMID: 16868035
7. Stockhausen M-T, Sjölund J, Manetopoulos C., Axelson H. Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer. 2005; 92: 751-9. doi: 10.1038/sj.bjc.6602309 PMID: 15685243
8. Shi G, Gao F, Jin Y. The regulatory role of histone deacetylase inhibitors in Fgf4 expression is dependent on the differentiation state of pluripotent stem cells. J Cell Physiol. 2011; 226:3190-3196. doi: 10.1002/jcp.22679 PMID: 21321941
9. Kretsovali A, Hadjimichael C, Charmpilas N. Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells Int. 2012; 2012:184154. doi: 10.1155/2012/184154 PMID: 22550500
10. Higuchi A, Ling Q-D, Kumar SS, Munusamy MA, Alarfaj AA, Chang Y, et al. Generation of pluripotent stem cells without the use of genetic material. Lab Invest. 2015; 95:26-42. doi: 10.1038/labinvest.2014.132 PMID: 25365202
11. De Felice L., Tatarelli C, Mascolo M.G., Gregorj C., Agostini F, Fiorini R, et al Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 2005; 65:1505-1513. doi: 10.1158/0008-5472.CAN-04-3063 PMID: 15735039
12. Burba I, Colombo GI, Staszewsky L.I., De Simone M, Devanna P, Nanni S., et al. Histone deacetylase inhibition enhances self renewal and cardioprotection by human cord blood-derived CD34 cells. PLoS One. 2011; 6: e22158. doi: 10.1371/journal.pone.0022158 PMID: 21789227
13. Feng J, Cen J, Li J, Zhao R., Zhu C, Wang Z, et al. Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail. Cell Adh Migr. 2015; 9:495-501. doi: 10.1080/19336918.2015.1112486 PMID: 26632346
14. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S, et al. Promoterhypomethylation regulates CD133 expression in human gliomas. Cell Res. 2008; 18:1037-46. doi: 10.1038/cr.2008.270 PMID: 18679414
15. Reya T, Morrison SJ, Clarke M.F., Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414:105-111. doi: 10.1038/35102167 PMID: 11689955
16. Kamijo T. Role of stemness-related molecules in neuroblastoma. Pediatr Res. 2012; 71:511-5. doi: 10.1038/pr.2011.54 PMID: 22430387
17. Lee A, Kessler JD, Read T.A., Kaiser C., Corbeil D, Huttner WB, et al. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci. 2005; 8: 723-729. doi: 10.1038/nn1473 PMID: 15908947
18. Singh SK, Hawkins C, Clarke I.D., Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004; 432:396-401. doi: 10.1038/nature03031 PMID: 15549107
19. Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question? Am J Transl Res. 2013; 5:563-581. PMID: 24093054
20. Baba T, Convery PA, Matsumura N, Whitaker R.S., Kondoh E., Perry T, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009; 28:209-18. doi: 10.1038/onc.2008.374 PMID: 18836486
21. Yi JM, Tsai H-C, Glöckner SC, Lin S., Ohm JE, Easwaran H, et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res. 2008; 68:8094-103. doi: 10.1158/0008-5472.CAN-07-6208 PMID: 18829568
22. Shmelkov SV, St Clair R, Lyden D, Rafii S. AC133/CD133/Prominin-1. Int J BiochemCell Biol. 2005; 37: 715-9. doi: 10.1016/j.biocel.2004.08.010 PMID: 15694831
23. Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis. 2011; 2: e200. doi: 10.1038/cddis.2011.80 PMID: 21881602
24. Yin S, Li J, Hu C., Chen X, Yao M, Yan M., et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity Int J Cancer. 2007; 120:1444-1450. doi: 10.1002/ijc.22476 PMID: 17205516
25. Tirino V, Desiderio V, D'Aquino R, De Francesco F, Pirozzi G, Graziano A., et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One. 2008; 3: e3469. doi: 10.1371/journal.pone.0003469 PMID: 18941626
26. Brescia P, Ortensi B, Fornasari L., Levi D, Broggi G, Pelicci G. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells. 2013; 31: 857-869. doi: 10.1002/stem.1317 PMID: 23307586
27. Wu CP, Xie M, Zhou L., Tao L, Zhang M, Tian J. Cooperation of side population cells with CD133 to enrich cancer stem cells in a laryngeal cancer cell line. Head Neck. 2013; 36:1279-1287. doi:10.1002/hed.23447
28. Vangipuram SD, Wang ZJ, Lyman WD Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents. Pediatr Blood Cancer. 2010; 54:361-368. doi: 10.1002/pbc.22351 PMID: 19927294
29. Koyama-Nasu R., Takahashi R, Yanagida S., Nasu-Nishimura Y, Oyama M, Kozuka-Hata H, et al. The Cancer Stem Cell Marker CD133 Interacts with Plakoglobin and Controls Desmoglein-2 Protein Levels. PLoS One. 2013; 8: e53710. doi: 10.1371/journal.pone.0053710 PMID: 23326490
30. O'Brien C.A., Pollett A, Gallinger S., Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficientmice. Nature. 2007; 445:106-110. doi: 10.1038/nature05372 PMID: 17122772
31. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F., et al. Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4. Cell Stem Cell. 2007; 1: 389-402. doi: 10.1016/j.stem.2007.08.001 PMID: 18371377
32. Wei Y, Jiang Y, Zou F., Liu Y, Wang S, Xu N., et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci USA. 2013; 110: 6829-34. doi: 10.1073/pnas.1217002110 PMID: 23569237
33. Opel D, Poremba C, Simon T., Debatin K-M, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 2007; 67: 735-45. doi: 10.1158/0008-5472.CAN-06-2201 PMID: 17234785
34. Pezzolo A, Parodi F, Marimpietri D., Raffaghello L, Cocco C, Pistorio A., et al. Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res. 2011; 21:1470-86. doi: 10.1038/cr.2011.38 PMID: 21403679
35. Tong Q-S, Zheng L-D, Tang S-T, Ruan Q-L, Liu Y, Li S-W, et al. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. WJP. 2008; 4:58-62. doi: 10.1007/s12519-008-0012-z PMID: 18402255
36. Sartelet H, Imbriglio T, Nyalendo C, Haddad E, Annabi B, Duval M, et al. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopa-thology 2012; 60:1144-1155. doi: 10.1111/j.1365-2559.2012.04191.x PMID: 22394107
37. Horst D, Scheel SK, Liebmann S, Neumann J., Maatz S, Kirchner T, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 2009; 219:427-434. doi: 10.1002/path.2597 PMID: 19621338
38. Shin JH, Lee YS, Hong Y-K, Kang CS. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas. J Neurooncol. 2013; 115: 333-41. doi: 10.1007/s11060-013-1234-z PMID: 24129546
39. Liu G, Yuan X, Zeng Z., Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006; 5: 67. doi: 10.1186/1476-4598-5-67 PMID: 17140455
40. Cinatl J, Gussetis ES, Cinatl J Jr., Ebener U, Mainke M, Schwabe D, Doerr HW, Kornhuber BGV. Differentiation arrest in neuroblastoma cell culture. J Cancer Res Clin Oncol. 1990; 116 Suppl: 9-14.
41. Shechter D, Dormann HL, Allis C.D., Hake SB. Extraction, purification and analysis of histones. Nat Protoc. 2007; 2:1445-1457. doi: 10.1038/nprot.2007.202 PMID: 17545981
42. Groh T, Hrabeta J, Khalil M.A., Doktorova H., Eckschlager T, Stiborova M. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. Int J Oncol. 2015; 47:343-52. doi: 10.3892/ijo.2015.2996 PMID: 25963435
43. Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian C.A., Usenko JK, et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood. 2004; 103: 2055-61. doi: 10.1182/blood-2003-06-1881 PMID: 14630820
44. Groh T, Hrabeta J, Poljakova J., Eckschlager T, Stiborova M. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells. Neuro Endocrinol Lett. 2012; 33 Suppl 3:16-24. Available: http://www.ncbi.nlm.nih.gov/pubmed/23353839 PMID: 23353839
45. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014; 73:495-501. doi: 10.1007/s00280-014-2384-1 PMID: 24435060
46. Khalil MA, Hrabeta J, Cipro S., Stiborova M, Vicha A, Eckschlager T. Neuroblastoma stem cells - Mechanisms of chemoresistance and histonedeacetylase inhibitors. Neoplasma. 2012. pp. 737-746. doi: 10.4149/neo-2012-093 PMID: 22862175
47. Phiel CJ, Zhang F, Huang E.Y., Guenther MG, Lazar MA, Klein PS. Histonedeacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001; 276: 36734-41. doi: 10.1074/jbc.M101287200 PMID: 11473107
48. Kovalevich J, Langford D. Considerations for the Use of SH - SY5Y Neuroblastoma Cells in Neurobiology. Methods Mol Biol. 2013; 1078: 9-21. doi: 10.1007/978-1-62703-640-5 PMID: 23975817
49. Poljaková J, Groh T, Gudino ZO, Hraběta J, Bořek-Dohalská L, Kizek R, et al. Hypoxia-mediated histone acetylation and expression of N-myc transcription factor dictate aggressiveness of neuroblastoma cells. Oncol Rep. 2014; 31:1928-34. doi: 10.3892/or.2014.2999 PMID: 24481548
50. Veas-Perez de Tudela M, Delgado-Esteban M, Cuende J, Bolaños JP, Almeida A. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. J Neurochem. 2010; 113: 819-25. doi: 10.1111/j.1471-4159.2010.06648.x PMID: 20180881
51. Meng X, Li M, Wang X., Wang Y, Ma D. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci. 2009; 100:1040-6. doi: 10.1111/j.1349-7006.2009.01144.x PMID: 19385971
52. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133 + and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008; 118: 2111-2120. doi: 10.1172/JCI34401 PMID: 18497886
53. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L., Hoek M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010; 70:719-29. doi: 10.1158/0008-5472.CAN-09-1820 PMID: 20068153
54. Griguer CE, Oliva CR, Gobin E, Marcorelles P., Benos DJ, Lancaster JR, et al. CD133 is a marker of bioenergeticstress in human glioma. PLoS One. 2008; 3: e3655. doi: 10.1371/journal.pone.0003655 PMID: 18985161
55. Barrantes-Freer A., Renovanz M, Eich M., Braukmann A, Sprang B, Spirin P., et al. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells. PLoSOne. 2015; 10: e0130519. doi: 10.1371/journal.pone.0130519 PMID: 26086074
56. Feng JM, Miao ZH, Jiang Y, Chen Y., Li JX, Tong LJ, et al. Characterization of the conversion between CD133+and CD133 - cells in colon cancer SW620 cell line. Cancer Biol Ther. 2012; 13:1396-1406. doi: 10.4161/cbt.22000 PMID: 22954703
57. Rizzino A. Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells. Wiley Interdiscip Rev Syst Biol Med. 2009; 1:228-36. doi: 10.1002/wsbm.12 PMID: 20016762
58. Hämmerle B., Yañez Y, Palanca S., Cañete A, Burks D.J., Castel V., et al. Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor. PLoS One. 2013; 8: e76761. doi: 10.1371/journal.pone.0076761 PMID: 24116151
59. Kaneko Y, Suenaga Y, Islam SMR, Matsumoto D, Nakamura Y., Ohira M, et al. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas. Cancer Sci. 2015; 106: 840-847. doi: 10.1111/cas.12677 PMID: 25880909
60. Ross RA, Biedler JL, Spengler BA A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors. Cancer Lett. 2003; 197:35-39. doi: 10.1016/S0304-3835(03)00079-XPMID: 12880957
61. Wakao S, Kuroda Y, Ogura F., Shigemoto T, Dezawa M. Regenerative Effects of Mesenchymal Stem Cells: Contribution of Muse Cells, a Novel Pluripotent Stem Cell Type that Resides in Mesenchymal Cells. Cells. 2012; 1:1045-60. doi: 10.3390/cells1041045 PMID: 24710542
62. Han L, Shi S, Gong T., Zhang Z, Sun X. Cancer stem cells: therapeutic implications and perspectives in cancer therapy. Acta Pharm Sin B. 2013; 3: 65-75. doi:10.1016/j.apsb.2013.02.006
63. Sun Y, Kong W, Falk A., Hu J, Zhou L, Pollard S., et al. CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS One. 2009; 4: e5498. doi: 10.1371/journal.pone.0005498 PMID: 19430532
64. O'Donovan N., Crown J, Stunell H. Caspase 3 in breast cancer. Clin Cancer Res. 2003; 9: 738-742. PMID: 12576443
65. Ma S, Lee TK, Zheng B-J, Chan KW, Guan X-Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008; 27:1749-1758. doi: 10.1038/sj.onc.1210811 PMID: 17891174
66. Ellis L, Ku S, Ramakrishnan S., Lasorsa E, Azabdaftari G, Godoy A., et al. Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. Oncotarget. 2013; 4: 2225-36. PMID: 24163230